Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No.	Product name	CAS No.	Purity
T36656	Anti-Spike-RBD Single Domain mAb		98%
T36656	Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity[1]. [1]. Chun...
T9931	Meplazumab	T9931	98%
T9931	meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
T35390	Magrolimab (anti-CD47)		98%
T35390
T35395	Camrelizumab (anti-PD-1)		98%
T35395
T9927	Panitumumab	339177-26-3	98%
T9927	Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
T39595	Disitamab vedotin	2136633-23-1	98%
T39595	Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated ...
T12706	Reslizumab	241473-69-8	98%
T12706	Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
T10497	Benralizumab	1044511-01-4	98%
T10497	Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced ...
T35389	Sarilumab (anti-IL-6Rα)		98%
T35389
T9923	Nimotuzumab	828933-51-3	98%
T9923	Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
T37535	Camrelizumab	1798286-48-2	98%
T37535	Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhib...
T9928	Ranibizumab	347396-82-1	98%
T9928	Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A
T36646	Trastuzumab deruxtecan	1826843-81-5	98%
T36646	Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of...
T36652	Anti-MERS-3A1 mAb		98%
T36652	Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MER...
T9924	Obinutuzumab	949142-50-1	98%
T9924	Obinutuzumab GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
T38362	Guselkumab	1350289-85-8	98%
T38362	Guselkumab is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. Guselkumab binds to human cynomolgus monkey IL-23 with Kd values of 3....
T11126	Durvalumab	1428935-60-7	98%
T11126	Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 n...
T9925	Ofatumumab	679818-59-8	98%
T9925	Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation
T35391	Vibostolimab (anti-TIGIT)		98%
T35391
T35394	Sintilimab (anti-PD-1)		98%
T35394